{
    "clinical_study": {
        "@rank": "4693", 
        "arm_group": [
            {
                "arm_group_label": "Formulation 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Formulation 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin aspart (NovoLog\u00ae)", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in the United States of America (USA). The aim of the trial is to\n      evaluate continuous subcutaneous infusion of NN1218 formulations and NovoLog\u00ae in subjects\n      with type 1 diabetes."
        }, 
        "brief_title": "A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog\u00ae in Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes mellitus (diagnosed clinically) for at least 12 months prior to the\n             screening visit (Visit 1)\n\n          -  Treatment with the same insulin analogue by CSII (continuous subcutaneous insulin\n             infusion) for the previous 3 months prior to the screening visit (Visit 1)\n\n          -  Using a MiniMed Paradigm\u00ae pump (515/715, 522/722 or 523/723) for the previous 6\n             months prior to the screening visit (Visit 1)\n\n          -  Glycosylated haemoglobin (HbA1c) below or equal to 9.0% by central laboratory\n\n          -  Body Mass Index (BMI) below or equal to 35.0 kg/m^2\n\n        Exclusion Criteria:\n\n          -  History of diabetic ketoacidsosis (DKA) episodes requiring hospitalization within 6\n             months prior to the screening visit (Visit 1)\n\n          -  History of abscess at the infusion site within 6 months prior to the screening visit\n             (Visit 1)\n\n          -  Hypoglycaemic unawareness as judged by the Investigator or history of severe\n             hypoglycaemic episodes requiring hospitalization within the last 6 months prior to\n             the screening visit (Visit 1)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682902", 
            "org_study_id": "NN1218-3930", 
            "secondary_id": "U1111-1121-5106"
        }, 
        "intervention": [
            {
                "arm_group_label": "Formulation 1", 
                "description": "Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.", 
                "intervention_name": "NN1218", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Formulation 2", 
                "description": "Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.", 
                "intervention_name": "NN1218", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin aspart (NovoLog\u00ae)", 
                "description": "Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 18, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Atlanta", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30318"
                }, 
                "name": "Novo Nordisk Clinical Trial Call Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog\u00ae in Subjects With Type 1 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Eva Gunge", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mean change in plasma glucose concentration", 
            "safety_issue": "No", 
            "time_frame": "From 0-2 hours after administration of standardised meal after the first, the second, and the third 14-day treatment period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682902"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Self-measured plasma glucose (SMPG) 7-point profile", 
                "safety_issue": "No", 
                "time_frame": "After the first, the second, and the third 14-day treatment period"
            }, 
            {
                "measure": "Self-measured plasma glucose (SMPG) 9-point profile", 
                "safety_issue": "No", 
                "time_frame": "After the first, the second, and the third 14-day treatment period"
            }, 
            {
                "measure": "Number of adverse events (AEs) (including infusion site reactions/infections)", 
                "safety_issue": "No", 
                "time_frame": "Days 0-14 for each treatment periods"
            }, 
            {
                "measure": "Number of hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Days 0-14 for each treatment periods"
            }, 
            {
                "measure": "Number of unexplained self-reported episodes of hypoglycaemia or hyperglycaemia (confirmed by SMPG)", 
                "safety_issue": "No", 
                "time_frame": "Days 0-14 for each treatment periods"
            }, 
            {
                "measure": "Number of episodes of infusion set occlusions", 
                "safety_issue": "No", 
                "time_frame": "Days 0-14 for each treatment periods"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}